Janus Henderson Group PLC increased its position in shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 29.6% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 32,400 shares of the biopharmaceutical company’s stock after purchasing an additional 7,400 shares during the quarter. Janus Henderson Group PLC owned approximately 0.06% of Agios Pharmaceuticals worth $2,729,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. Strs Ohio acquired a new stake in shares of Agios Pharmaceuticals during the 2nd quarter worth about $179,000. NewSquare Capital LLC acquired a new stake in shares of Agios Pharmaceuticals during the 2nd quarter worth about $182,000. Barrett Asset Management LLC acquired a new stake in shares of Agios Pharmaceuticals during the 2nd quarter worth about $253,000. M&T Bank Corp acquired a new stake in shares of Agios Pharmaceuticals during the 1st quarter worth about $293,000. Finally, Aperio Group LLC acquired a new stake in shares of Agios Pharmaceuticals during the 1st quarter worth about $311,000. Institutional investors and hedge funds own 93.63% of the company’s stock.
AGIO has been the subject of a number of recent analyst reports. Canaccord Genuity reiterated a “buy” rating and set a $90.00 target price on shares of Agios Pharmaceuticals in a research report on Wednesday, September 5th. Needham & Company LLC reissued a “buy” rating on shares of Agios Pharmaceuticals in a report on Thursday, August 2nd. Piper Jaffray Companies set a $125.00 price objective on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 2nd. SunTrust Banks reissued a “buy” rating and set a $123.00 price objective on shares of Agios Pharmaceuticals in a report on Monday, July 23rd. Finally, BidaskClub lowered shares of Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 26th. Six analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $96.27.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.62) by $0.43. The company had revenue of $40.40 million for the quarter, compared to analyst estimates of $12.47 million. Agios Pharmaceuticals had a negative net margin of 462.08% and a negative return on equity of 51.71%. The company’s revenue for the quarter was up 257.5% on a year-over-year basis. During the same quarter last year, the firm earned ($1.78) EPS. As a group, equities research analysts expect that Agios Pharmaceuticals Inc will post -6.11 EPS for the current year.
In other news, insider Scott Biller sold 3,000 shares of the firm’s stock in a transaction dated Friday, October 5th. The shares were sold at an average price of $69.79, for a total value of $209,370.00. Following the transaction, the insider now owns 53,932 shares of the company’s stock, valued at approximately $3,763,914.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Christopher Bowden sold 1,700 shares of the firm’s stock in a transaction dated Thursday, August 30th. The shares were sold at an average price of $80.03, for a total transaction of $136,051.00. Following the completion of the transaction, the insider now directly owns 1,224 shares in the company, valued at approximately $97,956.72. The disclosure for this sale can be found here. Insiders sold a total of 28,355 shares of company stock worth $2,148,062 in the last ninety days. Insiders own 3.02% of the company’s stock.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Further Reading: Penny Stocks, What You Need To Know
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.